TEH-TUBE
Tissue engineering of the right heart outflow tract by a biofunctionalized bioresorbable polymeric valved tube
| Coordinatore | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
Organization address
address: 3 Avenue Victoria contact info |
| Nazionalità Coordinatore | France [FR] |
| Sito del progetto | http://www.teh-tube.eu |
| Totale costo | 5˙744˙057 € |
| EC contributo | 4˙500˙962 € |
| Programma | FP7-NMP
Specific Programme "Cooperation": Nanosciences, Nanotechnologies, Materials and new Production Technologies |
| Code Call | FP7-NMP-2013-SME-7 |
| Funding Scheme | CP-TP |
| Anno di inizio | 2014 |
| Periodo (anno-mese-giorno) | 2014-01-01 - 2017-12-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
Organization address
address: 3 Avenue Victoria contact info |
FR (PARIS) | coordinator | 765˙880.00 |
| 2 |
CARDIO3 BIOSCIENCES SA
Organization address
address: RUE EDOUARD BELIN 12 contact info |
BE (MONT SAINT GUIBERT) | participant | 948˙060.00 |
| 3 |
HELMHOLTZ-ZENTRUM GEESTHACHT ZENTRUM FUR MATERIAL- UND KUSTENFORSCHUNG GMBH
Organization address
address: Max-Planck-Strasse 1 contact info |
DE (GEESTHACHT) | participant | 748˙034.00 |
| 4 |
STATICE SAS
Organization address
address: RUE THOMAS EDISON 9 contact info |
FR (BESANCON) | participant | 739˙902.00 |
| 5 |
RESCOLL
Organization address
address: ALLEE GEOFFROY SAINT HILAIRE 8 contact info |
FR (PESSAC) | participant | 676˙860.00 |
| 6 |
UNIVERSITY COLLEGE LONDON
Organization address
address: GOWER STREET contact info |
UK (LONDON) | participant | 368˙466.00 |
| 7 |
EURAM LIMITED
Organization address
address: "Tower House, Lucy Tower Street" contact info |
UK (LINCOLN) | participant | 253˙760.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Approximately 42% of infants’ mortality in the world is related to congenital heart defects (prevalence: 8-12/1000 births). Over 1/3 require the reconstruction of the right ventricular outflow tract (RVOT) by surgical procedures which currently use inert materials without any growth potential. Consequently, multiple reoperations are often required, with their attendant high risk of mortality and morbidity. The TEH-TUBE project will address these limitations by creating a novel bioabsorbable biomaterial using a polymeric valved tube either seeded with autologous adipose tissue derived stem cells (ADSC) or functionalized by a peptidic sequence triggering homing of the host cells onto the scaffold to make it a living self-populated structure. During the project we will: • Compare 3 different polymers (polydioxanone, polyhydroxyalkanoate, poly-ester-urethane-ureas) processed by electrospinning to generate a competent valved tube • Compare, in the selected polymer, ADSC seeding and peptide grafting using in vitro mechanical and biological tests as well as in vivo animal experiments (primarily rats) • Validate the ultimate combination (polymer cells or peptides) in a clinically relevant large animal model (in this case, the growing lamb to specifically assess the regenerative and growth potential of the composite construct) This stepwise approach will be conducted within a tightly controlled regulatory framework to ensure that the final product meets the current ATMP requirements for phase I/II clinical studies and, if successful, ultimate commercialization. Our TEH-TUBE project aims at developing an innovative biomaterial for the treatment of congenital heart abnormalities in children and young adults. By creating a material whose growth will keep pace with that of the patient, this product, geared to become an ATMP, should decrease the risk of reoperative surgeries, improve the quality of life and ultimately have a positive impact on healthcare costs.'